Christophe Pichavant

**** ****** **, ***. #*** ac1hi3@r.postjobfree.com

San Jose, CA 95124 1-404-***-****

SUMMARY

Highly experienced R&D scientist with expertise in cell & non-viral/viral gene therapy, and rare/orphan disease. Knowledgeable of in vitro and in vivo research with cells, plasmids, virus and animal models.

EDUCATION

2016 iFarm certificate (focused on improving efficiency of the commercialization of Stanford-owned inventions); Stanford University, Stanford, USA 2010 PhD; Laval University, Quebec City, Canada

RESEARCH EXPERIENCE

Postdoc/Research Associate, Stanford University 2014 - present Subject: Gene therapy in Limb Girdle Muscular Dystrophy, Dr. Calos lab

- Provide overall supervision of multiple lab projects/students and mouse colonies

- Design experiments to determine the efficiency of treatment in 3 different mouse models to measure disease improvement (in collaboration with Dr. Delp lab)

- Adapt assays for different variants of muscular dystrophies

- Validate first step of translation research: efficient non-viral gene therapy in mouse model Postdoc, Emory University 2011 - 2014

Subject: Regulation of myofiber branching in mouse muscles, Dr. Pavlath lab

- Collaborated on two first-author publications with lab team members and outside researcher

- Created a novel transgenic mouse model, now used in Germany for fundamental biology

- Characterized myofiber branching in mouse models to better understand what happens in Human in the context of aging, acute injury and muscle pathology MSc/PhD Student, Laval University 2005 - 2010

Thesis: Gene therapy in Duchenne muscular dystrophy / Use of dystrophin transgenes in the canine model, Dr. Tremblay lab

- International collaboration and teamwork allowed the publication of 3 research articles as first author in high-impact factor journals as well as 3 review articles and 2 second-author papers

- Successfully transplanted gene-edited muscle cells and delivered non-viral gene therapy in dog muscles to optimize our work for the treatment of non-human primate and dystrophic patients DUE DILIGENCE / MARKET ANALYSIS

2015-2016

Market Analysis and Business Development (internship), Mavericks Capital, San Mateo, CA

- Supported a healthcare investment bank firm to expand their marketing strategy

- Updated database of oncology biotech/pharma companies (public and private)

- Created valuation file of public companies based on financial metrics

- Analyzed past and present mergers & acquisitions in the Life Science tool & service segments Christophe Pichavant

3298 Kimber Ct, Apt. #145 ac1hi3@r.postjobfree.com

San Jose, CA 95124 1-404-***-****

Licensing strategy, Stanford University

- Supported Stanford Office of Technology and Licensing (OTL) through the optimization of their licensing strategy as part of the iFarm Team program at Stanford University.

- Performed competitive and SWOT analyses on the Liquid Biopsy segment and investigated market requirement and opportunities to identify potential clients Due Diligence of a public company, Stanford University

- Performed in-depth analysis/due diligence of the science, commercialization, regulation, finance and management of Osiris Therapeutics, a regenerative medicine products company

- Acquired fundamental due diligence skills during ‘Valuation of public company in the life science’ class (INDE239) held at Stanford University BUSINESS COMMUNAUTY LEADERSHIP

AIMS leadership/finance officer, Stanford University 2015 – 2017

- Organized talks/panels/networking events with leaders from science, technology and business

- Created successful collaborations/partnerships between Stanford postdoc community and leaders of biotech/venture industry around the Bay Area Co-president PhD Pathways, Stanford University 2016

- Co-supervised an extensive 1-day education event for the PhD and postdoc community with 80+ speakers and 300+ attendees. Co-managed budget of $35k Lab instructor, Emory University 2012 - 2014

- Taught and lectured basic laboratory techniques to undergraduate students

- Assisted in designing presentation & design/grade written and practice exam PUBLICATIONS (Selected subset from a total of over 10 peer-reviewed publications) Research article

Pichavant C, Burkholder TJ, Pavlath GK. Decrease of myofiber branching via muscle-specific expression of the olfactory receptor mOR23 in dystrophic muscle leads to protection against mechanical stress. Skeletal Muscle, 2016, 6:2

Simionescu-Bankston A1, Pichavant C1, Canner JP, Apponi LH, Wang Y, Steeds C, Olthoff JT, Belanto JJ, Ervasti JM, Pavlath GK. Creatine kinase B is necessary to limit myoblast fusion during myogenesis. Am J Physiol Cell Physiol. 2015; 308: C919–C931 1co-first author

Pichavant C, Aartsma-Rus A, Clemens PR, Davies KE, Dickson G, Takeda S, Wilton SD, Wolff JA, Wooddell CI, Xiao X, Tremblay JP. Current Status of Pharmaceutical and Genetic Therapeutic Approaches to Treat DMD. Mol Ther. 2011 May; 19(5): 830-40

Pichavant C, Chapdelaine P, Cerri DG, Dominique JC, Quenneville SP, Skuk D, Kornegay JN, Bizario JC, Xiao X, Tremblay JP. Expression of Dog Microdystrophin in Mouse and Dog Muscles by Gene Therapy. Mol Ther. 2010 May; 18(5): 1002-9.

Review article

Pichavant C, Aartsma-Rus A, Clemens PR, Davies KE, Dickson G, Takeda S, Wilton SD, Wolff JA, Wooddell CI, Xiao X, Tremblay JP. Current Status of Pharmaceutical and Genetic Therapeutic Approaches to Treat DMD. Mol Ther. 2011 May; 19(5): 830-40

Contact this candidate